Literature DB >> 17530167

Role of heregulin in human cancer.

M Breuleux1.   

Abstract

Heregulin (HRG) is a soluble secreted growth factor, which, upon binding and activation of ErbB3 and ErbB4 transmembrane receptor tyrosine kinases, is involved in cell proliferation, invasion, survival and differentiation of normal and malignant tissues. The HRG gene family consists of four members: HRG-1, HRG-2, HRG-3 and HRG-4, of which a multitude of different isoforms are synthesized by alternative exon splicing, showing various tissue distribution and biological activities. Disruption of the physiological balance between HRG ligands and their ErbB receptors is implicated in the formation of a variety of human cancers. The general mechanisms involved in HRG-induced tumorigenesis is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530167     DOI: 10.1007/s00018-007-7120-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  43 in total

1.  Embryonic requirements for ErbB signaling in neural crest development and adult pigment pattern formation.

Authors:  Erine H Budi; Larissa B Patterson; David M Parichy
Journal:  Development       Date:  2008-05-28       Impact factor: 6.868

Review 2.  Expression and function of ErbB receptors and ligands in the pituitary.

Authors:  Odelia Cooper; George Vlotides; Hidenori Fukuoka; Mark I Greene; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2011-10-27       Impact factor: 5.678

3.  Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains.

Authors:  Juan Carlos Montero; Ruth Rodríguez-Barrueco; Atanasio Pandiella
Journal:  J Biol Chem       Date:  2011-05-13       Impact factor: 5.157

4.  Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Authors:  Lisa C Schmitt; Alexander Rau; Oliver Seifert; Jonas Honer; Meike Hutt; Simone Schmid; Jonas Zantow; Michael Hust; Stefan Dübel; Monilola A Olayioye; Roland E Kontermann
Journal:  MAbs       Date:  2017-04-19       Impact factor: 5.857

5.  Neuregulin mediates F-actin-driven cell migration through inhibition of protein kinase D1 via Rac1 protein.

Authors:  Heike Döppler; Ligia I Bastea; Tim Eiseler; Peter Storz
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

6.  Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.

Authors:  Majid Momeny; Reza Ghasemi; Giovanni Valenti; Mariska Miranda; Ali Zekri; Ghazaleh Zarrinrad; Sepehr Javadikooshesh; Marjan Yaghmaie; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Tumour Biol       Date:  2015-10-19

7.  Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion.

Authors:  Rui Wang; Rajat Bhattacharya; Xiangcang Ye; Fan Fan; Delphine R Boulbes; Lee M Ellis
Journal:  Mol Cancer Res       Date:  2018-08-21       Impact factor: 5.852

8.  The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.

Authors:  Huiling He; Wei Li; Sandya Liyanarachchi; Yanqiang Wang; Lianbo Yu; Luke K Genutis; Sophia Maharry; John E Phay; Rulong Shen; Pamela Brock; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

9.  Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.

Authors:  Katsuaki Ieguchi; Masaaki Fujita; Zi Ma; Parastoo Davari; Yukimasa Taniguchi; Kiyotoshi Sekiguchi; Bobby Wang; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

10.  The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12.

Authors:  Lorena Hernandez; Tatiana Smirnova; Dmitriy Kedrin; Jeffrey Wyckoff; Liyin Zhu; E Richard Stanley; Dianne Cox; William J Muller; Jeffrey W Pollard; Nico Van Rooijen; Jeffrey E Segall
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.